Moclobemide treatment in multiple sclerosis patients with comorbid depression: An open-label safety trial

Yoram Barak*, Erel Ur, Anat Achiron

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

Depression is common in multiple sclerosis (MS) patients, but tricyclic compounds are not well tolerated and newer antidepressants have not been studied. Effects of 150-400 mg/day of moclobemide, a reversible monoamine oxidase A inhibitor, were studied in a 3-month open design in 10 MS patients with DSM-IV-diagnosed depression. Nine patients reached complete remission. No adverse effects were noted. Four patients reported side effects including nausea and insomnia. The authors conclude that moclobemide is a well tolerated and efficient treatment for depression comorbid with MS.

Original languageEnglish
Pages (from-to)271-273
Number of pages3
JournalJournal of Neuropsychiatry and Clinical Neurosciences
Volume11
Issue number2
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Dive into the research topics of 'Moclobemide treatment in multiple sclerosis patients with comorbid depression: An open-label safety trial'. Together they form a unique fingerprint.

Cite this